The Global Topical Drug Delivery Market Size is projected to grow at a CAGR of 6.3% from 2024 to 2031, according to a new report published by Verified Market Research ®. The report reveals that the ...

ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV ...

In an exclusive interview with Nigeria Health Watch, Dr Mukhtar outlined the Executive Order's two-year validity, and its transformative provisions. Central to this includes the removal of tariffs, ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Success can make companies complacent. Motorola, Gap, and Starbucks learned the hard way. Staying ahead means constantly ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

In August 2024, BioAge appointed Jean-Pierre Garnier, PhD, former CEO of GlaxoSmithKline, as Chair of the Board ... or clinical trial may not be replicated in subsequent trials or success in early ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

I think elections are like pregnancy. … Everyone puts all of the energy into D-day – the birth. We’ve had the gender reveal, but what really, really matters is what happens now and the path ahead.” ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from ...